1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 5:Aneurysm-related clinical outcomes
All Patients (N = 310) Patients with Coiling (n = 188) Patients with Flow Diverters (n = 122) P Value Mortality related to target aneurysm rupture or stroke 9 (2.9%) 5 (2.7%) 4 (3.3%) .15 Worsening of aneurysm-related symptoms 10 (3.2%) 7 (3.7%) 3 (2.5%) .79 Long-term good neurologic outcomes (mRS ≤ 2) 264 (85.2%) 155 (82.4%) 109 (89.3%) .33